The global PEGylated proteins market size reached US$ 1.16 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.13 Billion by 2028, exhibiting a growth rate (CAGR) of 10.16% during 2023-2028. The increasing prevalence of chronic diseases, the widespread product utilization in cancer treatment, and the escalating number of product approvals for PEGylated proteins represent some of the key factors driving the market.
PEGylated proteins are biomolecules that have been modified by covalent conjugation with polyethylene glycol (PEG). It involves the PEGylation technique that improves the pharmacokinetic behavior of the medicine by altering the biological molecule's physical and chemical characteristics, such as its conformation, electrostatic binding, and hydrophobicity. PEGylated proteins are widely used in therapeutic applications, such as vaccines, hormone replacement therapy, genetic disorders, anemia, and blood clotting disorder. It is also used in various drugs for diseases, including kidney disease, multiple sclerosis, hemophilia, and cancers. PEGylated proteins help in the extension of half-life, increasing stability, solubility, and proteolytic protection, reducing renal excretion, immunogenicity, and toxicity, and enhancing the efficacy of drug delivery. Besides this, PEGylated proteins are non-toxic, water-soluble, hydrophilic, non-antigenic, and non-immunogenic.
PEGylated Proteins Market Trends:
The rising prevalence of chronic diseases, such as kidney ailments, autoimmune diseases, genetic disorders, hepatitis, and rheumatoid arthritis across the globe is one of the key factors driving the market growth. PEGylated proteins are widely used to treat inflammation, deliver corrective genes to cells, prevent blood clots, deliver growth hormones, and prevent the progression of chronic kidney disease. In line with this, the widespread product utilization in cancer treatment to deliver chemotherapy drugs directly to cancer cells and reduce the side effects on healthy cells is favoring the market growth. Apart from this, various improvements in the PEGylation technology, such as the development of new PEGylation methods that can produce smaller and more complex molecules, are providing an impetus to the market growth. Additionally, the widespread adoption of PEGylation to improve the stability and half-life of colony-stimulating factors (CSFs), making them more effective as therapeutic agents, is acting as another growth-inducing factor. Furthermore, the rising adoption of protein-based drugs over non-protein-based drugs wherein PEGylation increases the circulation and half-life of the proteins, improving its efficiency, is propelling the market growth. Other factors, including the increasing number of product approvals for PEGylated proteins, development in the field of biotechnology and molecular biology engineering, the integration of PEG molecules in biopharmaceuticals and the associated advantages, rising geriatric population, and the implementation of various government initiatives to increase regulatory standards in the pharmaceutical industry, are anticipated drive the market further toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global PEGylated proteins market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on product, protein type, application, and end user.
- PEGylation Reagents
- PEGylation Kits
A detailed breakup and analysis of the PEGylated proteins market based on the product has also been provided in the report. This includes consumables (PEgylation reagents and PEgylation kits) and services. According to the report, consumables accounted for the largest market share.
Protein Type Insights:
- Colony Stimulating Factors
- Recombinant Factor VII
The report has provided a detailed breakup and analysis of the PEGylated proteins market based on the protein type. This includes colony stimulating factors, interferons, erythropoietin, mAbs, recombinant factor VII and others. According to the report, colony stimulating factors represented the largest segment.
- Cancer Treatment
- Chronic Kidney Diseases
- Multiple Sclerosis
- Gastrointestinal Disorders
A detailed breakup and analysis of the PEGylated proteins market based on the application has also been provided in the report. This includes cancer treatment, hepatitis, chronic kidney diseases, hemophilia, multiple sclerosis, gastrointestinal disorders, and others. According to the report, cancer treatment represented the largest segment.
End User Insights:
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic and Research Institutes
The report has provided a detailed breakup and analysis of the PEGylated proteins market based on the end user. This includes pharmaceutical and biotechnology companies, contract research organizations, and academic and research institutes. According to the report, pharmaceutical and biotechnology companies represented the largest segment.
- North America
- United Kingdom
- Asia Pacific
- South Korea
- Latin America
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for PEGylated proteins. Some of the factors driving the North America PEGylated proteins market included the rising geriatric population, increasing prevalence of chronic diseases, and extensive research and development (R&D).
The report has also provided a comprehensive analysis of the competitive landscape in the global PEGylated proteins market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abcam plc, Biomatrik Inc., Creative PEGWorks, Iris Biotech GmbH, JenKem Technology USA Inc., Laysan Bio Inc., NOF America Corporation (NOF Corporation), Profacgen, Thermo Fisher Scientific Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
|Base Year of the Analysis
||Consumables: PEGylation Reagents, PEGylation Kits
|Protein Types Covered
||Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VII, Others
||Cancer Treatment, Hepatitis, Chronic Kidney Diseases, Hemophilia, Multiple Sclerosis, Gastrointestinal Disorders, Others
|End Users Covered
||Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Abcam plc, Biomatrik Inc., Creative PEGWorks, Iris Biotech GmbH, JenKem Technology USA Inc., Laysan Bio Inc., NOF America Corporation (NOF Corporation), Profacgen, Thermo Fisher Scientific Inc., etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Benefits for Stakeholders:
- IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the PEGylated proteins market from 2017-2028.
- The research study provides the latest information on the market drivers, challenges, and opportunities in the global PEGylated proteins market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the PEGylated proteins industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.